Jefferies Group’s Amicus Therapeutics FOLD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2021
Q4
Sell
-25,829
Closed -$247K 1755
2021
Q3
$247K Buy
+25,829
New +$264K ﹤0.01% 1411
2021
Q2
Sell
-35,127
Closed -$347K 1772
2021
Q1
$347K Buy
35,127
+16,127
+85% +$250K ﹤0.01% 1209
2020
Q4
$439K Buy
19,000
+5,000
+36% +$102K ﹤0.01% 1181
2020
Q3
$198K Buy
+14,000
New +$204K ﹤0.01% 1188
2020
Q2
Sell
-6,898
Closed -$64K 1576
2020
Q1
$64K Sell
6,898
-51,502
-88% -$490K ﹤0.01% 1850
2019
Q4
$569K Buy
+58,400
New +$535K ﹤0.01% 1728
2019
Q3
Sell
-58,381
Closed -$729K 2803
2019
Q2
$729K Buy
+58,381
New +$741K 0.01% 1465
2019
Q1
Sell
-15,827
Closed -$152K 2425
2018
Q4
$152K Buy
+15,827
New +$174K ﹤0.01% 1900
2018
Q3
Sell
-13,705
Closed -$214K 2505
2018
Q2
$214K Buy
+13,705
New +$207K ﹤0.01% 2001
2017
Q2
Sell
-16,239
Closed -$131K 2304
2017
Q1
$116K Buy
+16,239
New +$103K ﹤0.01% 2117
2016
Q4
Sell
-15,000
Closed -$111K 2297
2016
Q3
$111K Buy
+15,000
New +$101K ﹤0.01% 2024
2016
Q2
Sell
-3,058
Closed -$26K 2222
2016
Q1
$26K Buy
+3,058
New +$21.7K ﹤0.01% 2084
2014
Q4
Sell
-100,000
Closed -$595K 2068
2014
Q3
$595K Buy
+100,000
New +$524K ﹤0.01% 1251

Other funds holding FOLD

Jefferies Group's FOLD Position: Q4 2021 in Review

Jefferies Group sold out of Amicus Therapeutics (FOLD) in Q4 2021, closing a stake of 25,829 shares — an estimated $247K sold.

Jefferies Group first reported a position in FOLD in Q3 2014 and held it in 13 quarters. The position peaked at $729K in Q2 2019. 223 funds tracked by Wall St. Rank hold FOLD as of Q4 2021.

  • Jefferies Group reported no remaining Amicus Therapeutics position as of Q4 2021 after selling out during the quarter.
  • Jefferies Group sold 25,829 Amicus Therapeutics shares in Q4 2021, an estimated $247K.
  • Jefferies Group first reported a position in Amicus Therapeutics in Q3 2014 and held it in 13 quarters.
  • Jefferies Group's Amicus Therapeutics position peaked at $729K in Q2 2019.
  • 223 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q4 2021.

Based on Jefferies Group's 13F filing for Q4 2021, filed 14 Feb 2022.